

Conatus Pharmaceuticals Inc.

Form 3

April 07, 2017

FORM 3**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB
Number: 3235-0104Expires: January 31,
2005Estimated average
burden hours per
response... 0.5**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person *

Â VANDERTIE MICHELLE L

(Last)

(First)

(Middle)

2. Date of Event Requiring
Statement

(Month/Day/Year)

03/31/2017

3. Issuer Name **and** Ticker or Trading Symbol
Conatus Pharmaceuticals Inc. [CNAT]4. Relationship of Reporting
Person(s) to Issuer5. If Amendment, Date Original
Filed(Month/Day/Year)

(Check all applicable)

☐ Director ☐ 10% Owner☒ Officer ☐ Other
(give title below) (specify below)

Vice President, Finance

C/O CONATUS

PHARMACEUTICALS

INC.,Â 16745 W. BERNARDO

DRIVE, SUITE 200

(Street)

SAN DIEGO,Â CAÂ 92127

(City)

(State)

(Zip)

6. Individual or Joint/Group
Filing(Check Applicable Line)☒ Form filed by One Reporting
Person☐ Form filed by More than One
Reporting Person**Table I - Non-Derivative Securities Beneficially Owned**1. Title of Security
(Instr. 4)2. Amount of Securities
Beneficially Owned
(Instr. 4)3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)4. Nature of Indirect Beneficial
Ownership
(Instr. 5)

Common Stock

4,978

I

See footnote. ⁽¹⁾Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.****Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**1. Title of Derivative Security
(Instr. 4)2. Date Exercisable and
Expiration Date
(Month/Day/Year)3. Title and Amount of
Securities Underlying
Derivative Security4. Conversion
or Exercise5. Ownership
Form of6. Nature of Indirect
Beneficial Ownership
(Instr. 5)

Edgar Filing: Conatus Pharmaceuticals Inc. - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	Â (2)	02/16/2021	Common Stock	3,636	\$ 0.99	D	Â
Stock Option (Right to Buy)	Â (3)	09/18/2023	Common Stock	15,000	\$ 9.61	D	Â
Stock Option (Right to Buy)	Â (4)	02/06/2024	Common Stock	15,000	\$ 9.45	D	Â
Stock Option (Right to Buy)	Â (5)	02/22/2025	Common Stock	15,000	\$ 6.4	D	Â
Stock Option (Right to Buy)	Â (6)	02/03/2026	Common Stock	15,000	\$ 1.85	D	Â
Stock Option (Right to Buy)	Â (2)	02/03/2026	Common Stock	3,750	\$ 1.85	D	Â
Stock Option (Right to Buy)	Â (7)	03/23/2026	Common Stock	20,000	\$ 2.09	D	Â
Stock Option (Right to Buy)	Â (8)	01/25/2027	Common Stock	23,000	\$ 4.21	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
VANDERTIE MICHELLE L C/O CONATUS PHARMACEUTICALS INC. 16745 W. BERNARDO DRIVE, SUITE 200 SAN DIEGO, CA 92127	Â	Â	Â Vice President, Finance	Â

Signatures

/s/ Michelle L.
Vandertie

04/07/2017

__Signature of Reporting
Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Held by family trust of which the Reporting Person is a trustee.

(2) Immediately exercisable.

(3) The option was granted on September 19, 2013. 25% of the total number of shares of common stock subject to the option vested on September 19, 2014, and 1/48th of the total number of shares of common stock subject to the option vest monthly thereafter, subject to

Edgar Filing: Conatus Pharmaceuticals Inc. - Form 3

the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

- (4) The option was granted on February 7, 2014. 25% of the total number of shares of common stock subject to the option vested on February 7, 2015, and 1/48th of the total number of shares of common stock subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

- (5) The option was granted on February 23, 2015. 25% of the total number of shares of common stock subject to the option vested on February 23, 2016, and 1/48th of the total number of shares of common stock subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

- (6) The option was granted on February 4, 2016. 25% of the total number of shares of common stock subject to the option vested on February 4, 2017, and 1/48th of the total number of shares of common stock subject to the option will vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

- (7) The option was granted on March 24, 2016. 25% of the total number of shares of common stock subject to the option vested on March 24, 2017, and 1/48th of the total number of shares of common stock subject to the option will vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

- (8) The option was granted on January 26, 2017. 25% of the total number of shares of common stock subject to the option will vest on January 26, 2018, and 1/48th of the total number of shares of common stock subject to the option will vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.